Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | GBA1 | P04062 | 2/20 | 0.42 |
| ▸ | ACHE | P22303 | 10/20 | 0.41 |
| ▸ | TNF | P01375 | 1/20 | 0.39 |
| ▸ | TLR4 | O00206 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL236414 | 1.00 | EPHX1 (0.47) | EPHX1GBA1ACHETNFTLR4 | |
| SCHEMBL3635575 | 1.00 | EPHX1 (0.47) | EPHX1GBA1ACHETNFTLR4 | |
| SCHEMBL8820095 | 0.94 | EPHX1 (0.42) | EPHX1GBA1ACHETNFTLR4 | |
| SCHEMBL8820100 | 0.94 | EPHX1 (0.42) | EPHX1GBA1ACHETNFTLR4 | |
| SCHEMBL5276297 | 0.89 | EPHX1 (0.42) | EPHX1ACHETLR4ADORA1 | |
| SCHEMBL1857528 | 0.87 | EPHX1 (0.47) | EPHX1ACHETLR4ADORA1 | |
| SCHEMBL3635578 | 0.84 | TLR4 (0.50) | EPHX1ACHETLR4 | |
| SCHEMBL60345 | 0.84 | TLR4 (0.50) | EPHX1ACHETLR4 | |
| SCHEMBL15870614 | 0.84 | TLR4 (0.50) | EPHX1ACHETLR4 | |
| SCHEMBL60344 | 0.84 | TLR4 (0.50) | EPHX1ACHETLR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2494983-B1 | STABLE FORMULATIONS OF GLP-1 | NOVO NORDISK AS (DK) | 2019-04-24 | — | — | EP | disclosed |
| EP-2190872-B1 | GLUCAGON-LIKE PEPTIDE-1 DERIVATIVES AND THEIR PHARMACEUTICAL USE | NOVO NORDISK AS (DK) | 2018-03-14 | — | — | EP | disclosed |
| US-9657079-B2 | Truncated GLP-1 derivatives and their therapeutical use | NOVO NORDISK A/S (DK) | 2017-05-23 | — | — | US | disclosed |
| US-9409966-B2 | Glucagon-like peptide-1 derivatives and their pharmaceutical use | NOVO NORDISK A/S (DK) | 2016-08-09 | — | — | US | disclosed |
| EP-1814581-B1 | STABLE FORMULATIONS OF PEPTIDES COMPRISING AN ACYLATED GLP-1 ANALOGUE AND A BASAL INSULINE | NOVO NORDISK AS (DK) | 2016-03-16 | — | — | EP | disclosed |
| EP-2322546-B1 | Acylated GLP-1 compounds | NOVO NORDISK AS (DK) | 2015-09-30 | — | — | EP | disclosed |
| EP-2190873-B1 | TRUNCATED GLP-1 DERIVATIVES AND THEIR THERAPEUTICAL USE | NOVO NORDISK AS (DK) | 2015-07-22 | — | — | EP | disclosed |
| US-9067977-B2 | Peptides derivatized with A-B-C-D- and their therapeutical use | NOVO NORDISK A/S (DK) | 2015-06-30 | — | — | US | disclosed |
| US-9012398-B2 | Acylated exendin-4 compounds | NOVO NORDISK A/S (DK) | 2015-04-21 | — | — | US | disclosed |
| US-20150025003-A1 | GLUCAGON-LIKE PEPTIDE-1 DERIVATIVES AND THEIR PHARMACEUTICAL USE | NOVO NORDISK AS (DK) | 2015-01-22 | — | — | US | disclosed |
| WO-2007135118-A1 | SOLUBLE, STABLE INSULIN-CONTAINING FORMULATIONS | NOVO NORDISK A/S (DK) | 2007-11-29 | — | — | WO | disclosed |
| WO-2007135117-A2 | SOLUBLE, STABLE INSULIN-CONTAINING FORMULATIONS | NOVO NORDISK A/S (DK) | 2007-11-29 | — | — | WO | disclosed |
| WO-2007104786-A1 | MIXTURES OF AMYLIN AND INSULIN | NOVO NORDISK A/S (DK) | 2007-09-20 | — | — | WO | disclosed |
| EP-1817048-A2 | STABLE FORMULATIONS OF INSULINOPTROPIC PEPTIDES | NOVO NORDISK A/S (DK) | 2007-08-15 | — | — | EP | disclosed |
| EP-1817049-A1 | SOLUBLE, STABLE INSULIN-CONTAINING FORMULATIONS WITH A PROTAMINE SALT | NOVO NORDISK A/S (DK) | 2007-08-15 | — | — | EP | disclosed |
| EP-1814581-A2 | STABLE FORMULATIONS OF PEPTIDES | NOVO NORDISK A/S (DK) | 2007-08-08 | — | — | EP | disclosed |
| WO-2006053906-A1 | SOLUBLE, STABLE INSULIN-CONTAINING FORMULATIONS WITH A PROTAMINE SALT | NOVO NORDISK A/S (DK) | 2006-05-26 | — | — | WO | disclosed |
| WO-2006051110-A2 | STABLE FORMULATIONS OF INSULINOPTROPIC PEPTIDES | NOVO NORDISK A/S (DK) | 2006-05-18 | — | — | WO | disclosed |
| WO-2006051103-A2 | STABLE FORMULATIONS OF PEPTIDES | NOVO NORDISK A/S (DK) | 2006-05-18 | — | — | WO | disclosed |
| US-6743781-B2 | COMPLEXING | TRANSGENE 6.A. (FR) | 2004-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025003-A1 | GLUCAGON-LIKE PEPTIDE-1 DERIVATIVES AND THEIR PHARMACEUTICAL USE | GLP1R, GIPR, GCGR | EPHX1 4145/4885GBA1 1953/4885ACHE 4417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.